OCC Orthocell Limited
—Mkt Cap: —P/E: —1d ago
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It o…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value91.69M USD
Revenue (TTM)7.88M USD
Gross Profit7.88M USD
Net Income (TTM)-9.62M USD
Revenue/Share0.04 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000OCC6
Valuation
P/E (Trailing)—
P/E (Forward)-43.33
PEG—
EV/EBITDA-7.46
EV/Revenue11.63
P/S15.52
P/B5.16
EPS (TTM)-0.05
EPS (Forward)-0.01
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin-159.75%
EBITDA Margin-155.83%
Profit Margin-121.98%
ROE-40.44%
ROA-25.39%
Growth
Revenue Growth42.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.80M USD
CapEx (TTM)876.81K USD
FCF Margin-86.01%
FCF Yield—
Net Debt-29.70M USD
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity0.03
Current Ratio5.97
Quick Ratio5.62
Book Value/Sh0.13 AUD
Cash/Share0.16 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.140 AUD
Target Range1.130 AUD – 1.150 AUD
# Analysts2
Ownership
Shares Out.272.39M
Float228.46M
Insiders16.60%
Institutions2.22%
Technical
SMA 500.7403 AUD
SMA 2000.8182 AUD
Beta-0.03
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)396.66K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—